The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     
 


Published online June 24, 2009
The Journal of Immunology, 2009, doi:10.4049/jimmunol.0900163
Copyright © 2009 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jimmunol.0900163v1
183/2/1488    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Kang, N.-I.
Right arrow Articles by Park, B.-H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kang, N.-I.
Right arrow Articles by Park, B.-H.
Right arrowPubmed/NCBI databases
*Substance via MeSH

A20 Attenuates Allergic Airway Inflammation in Mice1

Nam-In Kang*,2, Ha-Yong Yoon{dagger},2, Young-Rae Lee{dagger},2, Minho Won{ddagger}, Myoung Ja Chung{ddagger}, Jin-Woo Park{dagger}, Gang Min Hur§, Hern-Ku Lee* and Byung-Hyun Park{dagger},3

*Department of Immunology, {dagger}Department of Biochemistry, and {ddagger}Department of Pathology, Medical School and Diabetes Research Center, Chonbuk National University, Jeonju, Jeonbuk, Republic of Korea; and §Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

TNF receptor 1 can activate signaling pathways leading to the activation of NF-{kappa}B. A20, an NF-{kappa}B-inducible protein, negatively regulates these signaling pathways and acts as an anti-inflammatory mediator. Therefore, A20 is viewed as a potential therapeutic target for inflammatory disease. In this study, we examined the effect of A20 on an OVA-induced allergic airway inflammation model in mice. We used an adenovirus containing A20 cDNA (Ad-A20) that was delivered intratracheally before OVA challenge. Single administration of Ad-A20 reduced airway inflammatory cell recruitment and peribronchiolar inflammation and suppressed the production of various cytokines in bronchoalveolar fluid. In addition, Ad-A20 suppressed mucus production and prevented the development of airway hyperresponsiveness. The protective effect of Ad-A20 was mediated by the inhibition of the NF-{kappa}B signaling pathway. Taken together, our results suggest that the development of an immunoregulatory strategy based on A20 may have therapeutic potential for the treatment of allergic asthma.

3 Address correspondence and reprint requests to Dr. Byung-Hyun Park, Department of Biochemistry, Medical School, Chonbuk National University, Jeonju, Jeonbuk, Republic of Korea. E-mail address: bhpark{at}chonbuk.ac.kr

1 This work was supported by a grant from the Ministry of Science and Technology (MoST)/Korea Science and Engineering Foundation (KOSEF) through the Diabetes Research Center at Chonbuk National University (R13-2008-005-0000-0).

2 N.-I.K., H.-Y.Y., and Y.-R.L. contributed equally to this study.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
I. Martinez-Forero, A. Rouzaut, A. Palazon, J. Dubrot, and I. Melero
Lysine 63 Polyubiquitination in Immunotherapy and in Cancer-promoting Inflammation
Clin. Cancer Res., November 15, 2009; 15(22): 6751 - 6757.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.